Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease.

Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.

Biotechnology

Eidos Therapeutics

Neil Kumar

Suresh Siddhanti

Stuart Heminway

Satish Rao

Mamoun Alhamadsheh

Leonid K.

Jonathan Cascon

Janet Hsu

Isabella Graef

Ananth Sridhar

Jonathan Fox

Matt Outten

Uma Sinha

The leadership team at Eidos Therapeutics has a history of experience in the fields of academia, business development, and marketing. The team members have degrees from renowned institutions in a variety of disciplines, including microbilogy, immunology, chemical engineering, and psychology. This diverse background gives the team the ability to approach problems from multiple perspectives and find creative solutions.

Leadership Team

CEO and Executive Team

Board of Directors

Leadership Team

About

Team members

Other teams at Eidos Therapeutics

CEO and Executive Team

Board of Directors